Results 1 to 10 of about 274,774 (268)

The DNA Vaccines for the Gn and Gc Heterologous Polymer of Severe Fever with Thrombocytopenia Syndrome Virus Induce Potent Immunogenicity in Mice [PDF]

Vaccines
Introduction/Background: Severe fever with thrombocytopenia syndrome virus (SFTSV) poses a threat to global public health with a mortality rate of up to 30%. However, there is currently no commercialized SFTSV vaccine.
Qiuju He, Xiaojuan Liu, Jincheng Tong, Huan Li, Heng Zhang, Jiamin Chen, Mengyi Zhang, Zhihua Li, Qianqian Li   +8 more
doaj   +2 more sources

Novel enzymatic DNA produced from a text file achieves comparable immune responses as plasmid vaccine [PDF]

npj Vaccines
DNA vaccines have garnered considerable attention due to their recent success in humans for SARS-CoV-2 and immunotherapy for cancer. However, conventional methods for creating and manufacturing DNA vaccines at-scale are slow and rate-limiting for timely ...
James Fuller, Erik Kvam, Sandrine Creton, Courtney Hall, Nicholas J. Tursi, Kerry Blatney, Rebecca Ryan, Xavier Godron, David B. Weiner, Winston Timp, Weston Griffin, John Nelson, Deborah H. Fuller   +12 more
doaj   +2 more sources

Accounting Problems Under the Excess Profits Tax [PDF]

, 1943
DNA vaccines based on subunits from pathogens have several advantages over other vaccine strategies. DNA vaccines can easily be modified, they show good safety profiles, are stable and inexpensive to produce, and the immune response can be focused to the
A Biragyn, A Biragyn, A Biragyn, A Iwasaki, A Smed-Sorensen, A Viola, AB Fredriksen, AB Fredriksen, Agnete B. Fredriksen, AJ McMichael, AK Roos, B Ferraro, B Peng, Bjarne Bogen, BS Davis, C Cheong, C Coban, C Trumpfheller, D D’Ambrosio, DH Barouch, DP Snider, EB Compeer, EM Borroni, G Carayanniotis, G Grodeland, G Grodeland, G Nchinda, H Kawamura, H Qin, H Takahashi, HC Spang, I Oynebraten, Inger Øynebråten, J Aliberti, JD Altman, JJ Kim, Jorma Hinkula, K Ozato, KA Garver, KE Stephenson, KW Schjetne, L Cohn, L Norderhaug, L Qin, LJ Cruz, M Altfeld, M Charmoy, M Froyland, M Kreutz, M Mack, M Malissen, M Maurer, MA Liu, Mauricio M. Rodrigues, MS Neuberger, NY Sardesai, O Kew, OP Joffre, P Menten, PA Broliden, PA Ruffini, PF McKay, PJ Bergman, PJ Tacken, R Schiavo, R Song, RM Steinman, S Flingai, S Santra, T Schiffner, W Liu, WJ Karpus, WR Heath, Z Xiang   +73 more
core   +24 more sources

The potential of plant-based vaccines [PDF]

Future Natural Products, 2022
Plants are cost-effective biological delivery carrier. Plant-based vaccines are more reliable due to the lack of human pathogen or endotoxin, and oncogenic DNA.
Mahdi Ghatreh Samani
doaj   +1 more source

DNA Vaccines Encoding Antigen Targeted to MHC Class II Induce Influenza-Specific CD8+ T Cell Responses, Enabling Faster Resolution of Influenza Disease [PDF]

, 2016
Current influenza vaccines are effective but imperfect, failing to cover against emerging strains of virus and requiring seasonal administration to protect against new strains. A key step to improving influenza vaccines is to improve our understanding of
Bogen, B, Brunsvik Frediksen, A, Grodeland, G, Kinnear, E, Lambert, L, Lindberg, MM, Mcdonald, JU, Stubsrud, E, Tregoning, JS   +8 more
core   +12 more sources

Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation

Genome Medicine, 2021
Background Preclinical studies and early clinical trials have shown that targeting cancer neoantigens is a promising approach towards the development of personalized cancer immunotherapies. DNA vaccines can be rapidly and efficiently manufactured and can
Lijin Li, Xiuli Zhang, Xiaoli Wang, Samuel W. Kim, John M. Herndon, Michelle K. Becker-Hapak, Beatriz M. Carreno, Nancy B. Myers, Mark A. Sturmoski, Michael D. McLellan, Christopher A. Miller, Tanner M. Johanns, Benjamin R. Tan, Gavin P. Dunn, Timothy P. Fleming, Ted H. Hansen, S. Peter Goedegebuure, William E. Gillanders   +17 more
doaj   +1 more source

Have mRNA vaccines sentenced DNA vaccines to death?

Expert Review of Vaccines, 2023
Introduction After receiving emergency approval during the COVID-19 pandemic, mRNA vaccines have taken center stage in the quest to enhance future vaccination strategies for both infectious diseases and cancer.
Alberto Cagigi, Bruno Douradinha
doaj   +1 more source

Tick-Tattoo: DNA Vaccination Against B. burgdorferi or Ixodes scapularis Tick Proteins

Frontiers in Immunology, 2021
IntroductionBorrelia burgdorferi sensu lato (sl) is the causative agent of Lyme borreliosis. Currently there is no human vaccine against Lyme borreliosis, and most research focuses on recombinant protein vaccines. DNA tattoo vaccination with B.
Michelle J. Klouwens, Michelle J. Klouwens, Michelle J. Klouwens, Jos J. A. Trentelman, Alex Wagemakers, Jasmin I. Ersoz, Adriaan D. Bins, Adriaan D. Bins, Joppe W. Hovius, Joppe W. Hovius, Joppe W. Hovius   +10 more
doaj   +1 more source

Toward QbD Process Understanding on DNA Vaccine Purification Using Design of Experiment

Frontiers in Bioengineering and Biotechnology, 2021
DNA vaccines, the third generation of vaccines, are a promising therapeutic option for many diseases as they offer the customization of their ability on protection and treatment with high stability.
Lalintip Hocharoen, Sarawuth Noppiboon, Panit Kitsubun   +2 more
doaj   +1 more source

Responsiveness to basement membrane extract as a possible trait for tumorigenicity characterization

Vaccine: X, 2019
Immortalized cell lines used to produce vaccines are expected to be described in terms of their tumorigenicity. However, current in vivo tumorigenicity assays can be time-consuming and results can be equivocal, especially for weakly tumorigenic cells ...
Haruhiko Murata, Romelda Omeir, Wei Tu, Lynda Lanning, Kathryn Phy, Gideon Foseh, Andrew M. Lewis, Jr., Keith Peden   +7 more
doaj   +1 more source